OKYO Pharma Limited OKYO 深 沪
等待开盘 02-06 09:30:00 美东时间
1.885
-0.075
-3.83%
华盛通- 最 高1.9987
- 今 开1.93
- 成交量 5.43万股
- 最 低 1.87
- 昨 收 1.96
- 总市值 7089.62万
- 52周最高 3.349
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 1.03
- 委 比 -89.57%
- 总股本 3761.07万
- 历史最高 7.00
- 量 比 0.94
- 振 幅 6.57%
- 历史最低 0.8075
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OKYO Pharma Announces Successful Type C Meeting with the FDA
OKYO Pharma confirms successful FDA Type C meeting for urcosimod's Phase 2b/3 trial for neuropathic corneal pain (NCP). FDA approved primary endpoint of VAS pain reduction at Week 12, statistical guidance, and study design, including sample size and OPAS as supportive evidence. FDA also aligned on CMC strategy, derisking pivotal trial and supporting potential registration. Urcosimod has Fast Track designation and plans to initiate a 120-patient t...
01-28 12:40
BRIEF-FDA Approves Compassionate Use Of Urcosimod (0.05%) For The Treatment Of Neuropathic Corneal Pain
BRIEF-FDA Approves Compassionate Use Of Urcosimod (0.05%) For The Treatment Of Neuropathic Corneal Pain Jan 23 (Reuters) - OKYO Pharma Ltd OK11.MU : FDA APPROVES COMPASSIONATE USE OF URCOSIMOD (0.05%) FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN OKYO PHARMA LTD - TO INITIATE 120-PATIENT STUDY OF UR
01-23 20:01
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
<p>OKYO Pharma获得了FDA对urcosimod用于治疗一名神经性角膜痛患者的授权。这是首个针对NCP的IND，并获得了快速通道资格。公司计划启动一项120患者的2b/3期试验。NCP是一种严重眼部疼痛疾病，目前无FDA批准的治疗方法。Urcosimod通过抑制免疫炎症和神经信号有望缓解症状。OKYO致力于开发创新疗法以解决该领域的迫切需求。</p>
01-23 12:00
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 19.2% to $1...
01-09 20:05
OKYO Pharma Appoints Robert Dempsey As CEO
Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertiseGary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the BoardLONDON and
01-05 20:19
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
OKYO Pharma appoints Robert J. Dempsey as CEO, bringing extensive experience in ophthalmologyCommercialization and development of successful eye therapies like Xiidra® and Restasis®. Gary S. Jacob, Ph.D., transitions to Chief Development Officer, continuing his role on the Board. The company focuses on advancing urcosimod for neuropathic corneal pain and inflammatory eye diseases, poised for growth under Dempsey's leadership.
01-05 12:00
OKYO Pharma to Ring the Opening Bell at Nasdaq
OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing urcosimod for neuropathic corneal pain (NCP), announced its Executive Chairman Gabriele Cerrone and management will ring the Nasdaq Opening Bell in New York, celebrating the company's advancements in innovative treatments. The ceremony highlights urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, with recent positive Phase 2 results show...
2025-12-19 12:00
OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. On Decemb...
2025-12-15 21:58
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Limited，专注于眼科药物开发的生物制药公司，宣布其董事长Gabriele Cerrone通过Panetta Partners Limited增持24,551股，使总持股增至10,516,297股。其药物Urcosimod在干眼症和神经性角膜疼痛的二阶段试验中均显示显著疗效，用于治疗这两种慢性眼疾。
2025-12-15 13:30
OKYO Pharma Announces New Analyses Of Corneal Images From Placebo-Controlled, Randomized, Double-Masked, Phase 2 Clinical Trial Of Urcosimod In Neuropathic Corneal Pain
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a
2025-12-11 21:38
